Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Outcomes Post-AlloSCT in DHL/DEL Lymphomas

Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al

Allogeneic stem cell transplantation (alloSCT) should be considered in patients with double-expressor lymphomas (DEL) and double-hit lymphomas (DHL), researchers concluded after conducting a retrospective analysis involving 78 individuals. Participants underwent alloSCT for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Investigators looked at the impact of DEL/DHL status. Among the results:

  • 47% had DEL and 13% DHL.
  • 4-year progression-free and overall survival rates were similar in patients with and without either DEL or DHL.
  • The findings held up after multivariate analysis, though researchers acknowledged the sample size might have prevented detecting significant differences.

Citation:

Herrera A, Rodig S, Song J, et al. Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma. [Published online ahead of print November 28, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.11.023.

This Week's Must Reads

Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052

Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.

Oral administration of arsenic + ATRA effective for APML, Zhu HH et al. Lancet Oncol. 2018;19:871-9.

Must Reads in Aggressive Lymphomas

Escalating venetoclax dose was safe in relapsed CLL, Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

Ibrutinib and venetoclax for relapsed CLL, Niemann C et al. European Society of Hematology Annual Congress 2018. Abstract PF346.

Durable responses seen from lisocabtagene in relapsed/refractory DLBCL, Abramson JS et al. ASCO 2018. Abstract 7505

ADC + BR improves response rate in diffuse large B-cell lymphoma, Sehn LH et al. EHA Congress, Abstract S802.